Researchers at the University of Sydney developed nasal drops containing mRNA molecules—instructions that tell cells how to make proteins. The treatment essentially turns cells in the nose into tiny drug factories producing BDNF, a protein that supports neuron survival and memory formation.
⚙️ The proteins produced in the nose can travel to the brain along the olfactory nerve, bypassing the blood-brain barrier. After receiving the treatment, older mice performed just as well as younger mice on tests of working memory, spatial memory, and object recognition.
The drops were tested in genetically modified mice that develop Alzheimer's-like disease. These mice typically show serious cognitive decline by four months. But those that began receiving the mRNA treatment at two months showed no memory decline.
Interestingly, the amyloid plaques associated with Alzheimer's were still present in their brains. The treatment appeared to help neurons keep functioning despite the underlying disease.
💡 Mice have short nasal passages and a relatively large olfactory region, making it easier for proteins to reach the brain. In humans, that region lies much deeper inside the nasal cavity, so researchers will need to adapt the delivery method and determine the right dosage. Still, the team is optimistic about the treatment's potential.
"Based on previous clinical trials, we know the components used in this study to be safe in humans. We hope we can move quickly through the requisite safety studies and trial this treatment in humans in the next two years," says Professor Greg Neely, who leads the research lab.
@hiaimediaen
